BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis

BIT:1BMY • US1101221083

51.02 EUR
-0.02 (-0.04%)
Last: Feb 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

1BMY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of 1BMY get a neutral evaluation. Nothing too spectacular is happening here. 1BMY has a bad growth rate and is valued cheaply. Finally 1BMY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year 1BMY was profitable.
  • In the past year 1BMY had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
  • Of the past 5 years 1BMY 4 years had a positive operating cash flow.
1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B

1.2 Ratios

  • 1BMY has a Return On Assets (6.23%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of 32.55%, 1BMY is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
  • 1BMY's Return On Invested Capital of 17.49% is fine compared to the rest of the industry. 1BMY outperforms 74.55% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1BMY is below the industry average of 14.21%.
  • The last Return On Invested Capital (17.49%) for 1BMY is above the 3 year average (11.67%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 17.49%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1BMY.MI Yearly ROA, ROE, ROIC1BMY.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

  • 1BMY has a Profit Margin of 12.57%. This is comparable to the rest of the industry: 1BMY outperforms 49.09% of its industry peers.
  • The Operating Margin of 1BMY (33.51%) is better than 81.82% of its industry peers.
  • 1BMY's Operating Margin has declined in the last couple of years.
  • 1BMY has a Gross Margin (73.15%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of 1BMY has remained more or less at the same level.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
1BMY.MI Yearly Profit, Operating, Gross Margins1BMY.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1BMY is creating value.
  • There is no outstanding debt for 1BMY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1BMY.MI Yearly Shares Outstanding1BMY.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
1BMY.MI Yearly Total Debt VS Total Assets1BMY.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • 1BMY has an Altman-Z score of 2.33. This is not the best score and indicates that 1BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
  • 1BMY has a Altman-Z score (2.33) which is in line with its industry peers.
  • 1BMY has a debt to FCF ratio of 3.20. This is a good value and a sign of high solvency as 1BMY would need 3.20 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.20, 1BMY is in the better half of the industry, outperforming 67.27% of the companies in the same industry.
  • 1BMY has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 2.41, 1BMY is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.33
ROIC/WACC2.02
WACC8.67%
1BMY.MI Yearly LT Debt VS Equity VS FCF1BMY.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that 1BMY should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.27, 1BMY is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
  • A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.17, 1BMY is in the better half of the industry, outperforming 69.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
1BMY.MI Yearly Current Assets VS Current Liabilites1BMY.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • 1BMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 439.47%, which is quite impressive.
  • 1BMY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.92% yearly.
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%

3.2 Future

  • Based on estimates for the next years, 1BMY will show a decrease in Earnings Per Share. The EPS will decrease by -3.16% on average per year.
  • Based on estimates for the next years, 1BMY will show a decrease in Revenue. The Revenue will decrease by -5.36% on average per year.
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
1BMY.MI Yearly Revenue VS Estimates1BMY.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
1BMY.MI Yearly EPS VS Estimates1BMY.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 9.85 indicates a reasonable valuation of 1BMY.
  • Based on the Price/Earnings ratio, 1BMY is valued cheaper than 90.91% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.67. 1BMY is valued rather cheaply when compared to this.
  • 1BMY is valuated reasonably with a Price/Forward Earnings ratio of 9.96.
  • 85.45% of the companies in the same industry are more expensive than 1BMY, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of 1BMY to the average of the S&P500 Index (27.69), we can say 1BMY is valued rather cheaply.
Industry RankSector Rank
PE 9.85
Fwd PE 9.96
1BMY.MI Price Earnings VS Forward Price Earnings1BMY.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 1BMY is valued cheaply inside the industry as 92.73% of the companies are valued more expensively.
  • 1BMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1BMY is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.06
EV/EBITDA 7.37
1BMY.MI Per share data1BMY.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as 1BMY's earnings are expected to decrease with -3.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • 1BMY has a Yearly Dividend Yield of 4.23%, which is a nice return.
  • 1BMY's Dividend Yield is rather good when compared to the industry average which is at 1.94. 1BMY pays more dividend than 85.45% of the companies in the same industry.
  • 1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 4.23%

5.2 History

  • The dividend of 1BMY is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1BMY pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
  • 1BMY's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP82.81%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
1BMY.MI Yearly Income VS Free CF VS Dividend1BMY.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B
1BMY.MI Dividend Payout.1BMY.MI Dividend Payout, showing the Payout Ratio.1BMY.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BRISTOL-MYERS SQUIBB CO

BIT:1BMY (2/12/2026, 7:00:00 PM)

51.02

-0.02 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)04-30
Inst Owners81.87%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap103.86B
Revenue(TTM)N/A
Net Income(TTM)6.04B
Analysts70
Price Target48.75 (-4.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.23%
Yearly Dividend2.05
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)7.65%
PT rev (3m)9.84%
EPS NQ rev (1m)-32.03%
EPS NQ rev (3m)-28.42%
EPS NY rev (1m)-8.25%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)1.43%
Valuation
Industry RankSector Rank
PE 9.85
Fwd PE 9.96
P/S 2.57
P/FCF 8.06
P/OCF 7.42
P/B 6.65
P/tB N/A
EV/EBITDA 7.37
EPS(TTM)5.18
EY10.15%
EPS(NY)5.12
Fwd EY10.05%
FCF(TTM)6.33
FCFY12.41%
OCF(TTM)6.88
OCFY13.48%
SpS19.87
BVpS7.67
TBVpS-9.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number29.91
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 17.49%
ROICexc 22.99%
ROICexgc 117.18%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.33
F-Score6
WACC8.67%
ROIC/WACC2.02
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)439.47%
EPS 3Y-7.62%
EPS 5Y-0.92%
EPS Q2Q%-24.55%
EPS Next Y-1.05%
EPS Next 2Y-1.88%
EPS Next 3Y-3.16%
EPS Next 5Y-3.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.3%
Revenue Next Year-7.97%
Revenue Next 2Y-5.07%
Revenue Next 3Y-5.93%
Revenue Next 5Y-5.36%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year220.11%
EBIT Next 3Y49.61%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%

BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ

Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a fundamental rating of 4 / 10 to 1BMY.MI.


Can you provide the valuation status for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a valuation rating of 7 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.


Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?

BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.


Can you provide the financial health for 1BMY stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 4 / 10.


Is the dividend of BRISTOL-MYERS SQUIBB CO sustainable?

The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 7 / 10 and the dividend payout ratio is 82.81%.